



(11) **EP 3 562 485 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 31/4045 ^(2006.01) **A61K 45/06** ^(2006.01)
A61K 9/22 ^(2006.01) **A61K 9/50** ^(2006.01)
A61P 15/16 ^(2006.01)

(48) Corrigendum issued on:
19.08.2020 Bulletin 2020/34

(86) International application number:
PCT/EP2019/057267

(45) Date of publication and mention of the grant of the patent:
01.07.2020 Bulletin 2020/27

(87) International publication number:
WO 2019/180217 (26.09.2019 Gazette 2019/39)

(21) Application number: **19714150.0**

(22) Date of filing: **22.03.2019**

(54) **NON-HORMONAL COMPOSITIONS AND METHODS FOR MALE CONTRACEPTION COMPRISING (R)-SILODOSIN**

NICHT-HORMONELLE ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MÄNNLICHEN KONTRAZEPTION ENTHALTEND (R)-SILODOSIN

COMPOSITIONS ET PROCÉDÉS NON HORMONAUX POUR LA CONTRACEPTION MASCULINE AVEC (R)-SILODOSIN

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Validation States:
KH MA TN

- **PERRIN, Philippe**
75015 Paris (FR)
- **DROUPY, Stéphane**
30900 Nîmes (FR)
- **AGATHON-MERIAU, Véronique**
92500 Rueil-Malmaison (FR)

(30) Priority: **23.03.2018 EP 18305328**
23.03.2018 US 201862763129 P

(74) Representative: **Icosa**
83 avenue Denfert-Rochereau
75014 Paris (FR)

(43) Date of publication of application:
06.11.2019 Bulletin 2019/45

(56) References cited:
CN-B- 102 283 816

(60) Divisional application:
20182691.4

(73) Proprietor: **Laboratoires Major**
75116 Paris (FR)

(72) Inventors:
• **EL GLAOU, Guillaume**
75008 Paris (FR)
• **EL GLAOU, Medhi**
75008 Paris (FR)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 562 485 B8

- BHATG ET AL: "BKP 02 Prospective double blind randomised study to evaluate the efficacy of Sildenafil 8 mg as on demand, reversible, male oral contraceptive", INDIAN JOURNAL OF UROLOGY, MEDKNOW PUBLICATIONS AND MEDIA PVT. LTD, IN , vol. 34, no. 5, Supplement 1 1 January 2018 (2018-01-01), page S7, XP009507905, ISSN: 1998-3824 Retrieved from the Internet:
URL:<http://www.indianjurol.com/text.asp?2018/34/5/7/222931>
- JIN WANG ET AL: "Assessment of Tamsulosin as a Potential Male Contraceptive in Healthy Volunteers", UROLOGY., vol. 80, no. 3, 1 September 2012 (2012-09-01), pages 614-617, XP055240673, US ISSN: 0090-4295, DOI: 10.1016/j.urology.2012.06.003 cited in the application
- CHEN Y ET AL: "Blockade of alpha1A-adrenoceptor: A novel possible strategy for male contraception", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 73, no. 2, 1 August 2009 (2009-08-01) , pages 140-141, XP026124106, ISSN: 0306-9877, DOI: 10.1016/J.MEHY.2009.02.022 [retrieved on 2009-05-08]
- KOBAYASHI K ET AL: "ORGASM IS PRESERVED REGARDLESS OF EJACULATORY DYSFUNCTION WITH SELECTIVE ALPHA-1A-BLOCKER ADMINISTRATION", EUROPEAN UROLOGY SUPPLEMENTS, ELSEVIER BV, NL, vol. 7, no. 3, 1 March 2008 (2008-03-01), page 186, XP022610457, ISSN: 1569-9056, DOI: 10.1016/S1569-9056(08)60457-1 [retrieved on 2008-03-01]
- KJAERGAARD N ET AL: "Prazosin, an adrenergic blocking agent inadequate as male contraceptive pill", CONTRACEPTION, GERON-X, INC., LOS ALTOS, CA, US, vol. 37, no. 6, 1 June 1988 (1988-06-01), pages 621-629, XP023167444, ISSN: 0010-7824, DOI: 10.1016/0010-7824(88)90008-X [retrieved on 1988-06-01]